MedTrace Logo

Phase II Study of Dasatinib (BMS-354825) for Androgen-deprived Progressive Prostate Cancer

NCT00385580 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2013-04-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to learn if men with metastatic prostate cancer and rising Prostate Specific Antigen (PSA), who have been surgically castrated or are undergoing androgen deprivation with Luteinizing Hormone Releasing Hormone (LHRH) treatment, respond to dasatinib. The safety of this treatment will also be studied.

Conditions

Interventions

DRUG

dasatinib

Tablets, Oral, 100 mg or 70 mg, twice daily, treatment may continue until disease progression

DRUG

dasatinib

Tablets, Oral, 100 mg, once daily (QD) treatment may continue until disease progression

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-12-31
Completion
2010-10-31

Countries

  • United States
  • France
  • Italy

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00385580 on ClinicalTrials.gov